Gilead shares rise on improved Sovaldi sales predictions; Novartis sues alleging Zortress patent infringement;

@FiercePharma: Merck KGaA negotiates huge production deal with Lupin. ICYMI yesterday from FiercePharmaManufacturing | Follow @FiercePharma

@EricPFierce: MannKind says it and partner Sanofi can fatten their margins on Afrezza by using Sanofi API. Story | Follow @EricPFierce

@CarlyHFierce: AstraZeneca sends James Van Der Beek 'camping' to promote flu vaccination. Article from FiercePharmaMarketing | Follow @CarlyHFierce

> Shares of Gilead Sciences ($GILD) stock rose in afternoon trading Tuesday as FBR analyst Andrew Berens raised his Q3 Sovaldi sales forecast. Report

> AstraZeneca ($AZN) has inaugurated a new Global Technology Center in Chennai, India, to develop its IT capability. Report

> Novartis ($NVS) has sued generics maker Roxane Laboratories over patent infringement on organ rejection drug Zortress. More (sub. req.)

> Almost 90 lives could be saved every year if almost all teenage girls were given HPV vaccines, experts say. Report

> Two U.S. lawmakers are calling for action to curb antibiotic use on farms. More

> A public petition to force Roche ($RHHBY) to lower the cost of breast cancer drug Kadcyla has been spread online by a British disease survivor. More

> The risk of endophthalmitis is 65% higher following treatment with Bayer and Regeneron's ($REGN) Eylea than treatment with Novartis ($NVS) and Roche's ($RHHBY) Lucentis, new data show. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Researchers at Harvard's Wyss Institute develop dialysis device to fight Ebola. Article | Follow @FierceMedDev

@MichaelGFierce: Vaxxas' nanopatch garners WHO support in search of #polio vax application. More | Follow @MichaelGFierce

@VarunSaxena2: ICYMI: St. Jude halts Portico TAVR implants over safety concerns. Story | Follow @VarunSaxena2

@EmilyWFierce: IVF grows by leaps and bounds as 1% of U.S. babies are conceived through assisted reproductive technology. Story via The Atlantic | Follow @EmilyWFierce

> Medtronic unloads instrument lines to Integra for $60M. Story

> FDA takes step toward standardized medical device labeling. Article

> Avinger raises $35M for PAD catheter that combines imaging and treatment. News

Biotech News

@FierceBiotech: From yesterday's FierceBiotechResearch: Human stem cells can be 'reset' to their earliest state. Article | Follow @FierceBiotech

@JohnCFierce: Novo is looking to base a new obesity R&D group in Seattle, which would be great for them. More from Bloomberg | Follow @JohnCFierce

@DamianFierce: Oxygen Bio will soon be Tenax Therapeutics. $OXBT to $TENX. Release | Follow @DamianFierce

@EmilyMFierce: Naturally occurring antibiotic found in human bacterial colony. FierceBiotech Research story | Follow @EmilyMFierce

> Gilead's oncology contender comes up short in pancreatic cancer. Story

> Sutro adds Merck KGaA to its roster of marquee 'armed antibody' partners. More

> Tokai pockets $97M in IPO cash to get its cancer drug into Phase III. Article

> Sanofi partners with MyoKardia on a 'totally new' approach to heart disease. Report

Drug Delivery News

> Researchers deploy nanoparticles that can alter packaging of DNA. Item

> Vaxxas' nanopatch garners WHO support in search of polio vax application. Story

> Civitas, NeuroDerm, EyeGate to pursue IPO dreams, combined $165M on the line. Article

> Drug delivery specialist Genisphere receives an additional $2M in funding. News

> Market research firm: RNA-based drugs to exceed $1B in sales by 2020. Report

Diagnostics News

> Gene-sequencing leukemia research could boost Dx and treatment for kids with a rare disease subtype. More

> Pittsburgh outfit launches blood Dx to measure pediatric transplant rejection risk. Report

> Belgium's VolitionRx touts positive early results for noninvasive colon cancer Dx. Story

> Amarantus scores a small victory in the advance of its Alzheimer's Dx test. More

> BG Medicine slashes staff before launching automated version of heart failure test. Article

Pharma Marketing News

> AZ faces market-making task to capitalize on Movantik's edge in OIC. Article

> Sanofi, MannKind say cutting insulin costs will make Afrezza more competitive. Item

> First-to-market launch? Bonus--but double bonus if you're Big Pharma. More

> AstraZeneca sends James Van Der Beek 'camping' to promote flu vaccination. Story

> Xtandi field force gets a staffing boost for market-share battle with Zytiga. Article

And Finally... Sitting less can slow the aging process within cells, and standing up--even if you're standing still--can be good for you as well, two new studies show. More

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.